» Articles » PMID: 32083035

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir

Overview
Specialty Gastroenterology
Date 2020 Feb 22
PMID 32083035
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen.

Methods: This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done.

Results: Our results showed a statistically significant decrease in serum NGAL (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (.

Conclusions: Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection.

Citing Articles

Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections.

Chen F, Wu S, Chen C, Zhou C World J Hepatol. 2024; 16(2):177-185.

PMID: 38495277 PMC: 10941746. DOI: 10.4254/wjh.v16.i2.177.


Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.

Chen Y, Li C, Ko P, Lee C, Syu R, Tseng C PLoS One. 2021; 16(8):e0256505.

PMID: 34437608 PMC: 8389462. DOI: 10.1371/journal.pone.0256505.


Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals.

Elzorkany K, Kora M, Abdel Wahed A, Zaghla H, Zahran A, Yassein Y Int J Nephrol Renovasc Dis. 2020; 13:351-358.

PMID: 33273842 PMC: 7705253. DOI: 10.2147/IJNRD.S275721.

References
1.
Kouyoumjian S, Chemaitelly H, Abu-Raddad L . Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018; 8(1):1661. PMC: 5785953. DOI: 10.1038/s41598-017-17936-4. View

2.
Lin Z, Xin Y, Dong Q, Wang Q, Jiang X, Zhan S . Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3):726-36. DOI: 10.1002/hep.24105. View

3.
Garimella T, Wang R, Luo W, Hwang C, Sherman D, Kandoussi H . Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015; 20(5):535-43. DOI: 10.3851/IMP2941. View

4.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

5.
Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, DOnofrio G, Postorino M . Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?. World J Hepatol. 2016; 8(19):815-24. PMC: 4937169. DOI: 10.4254/wjh.v8.i19.815. View